Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 July 2024 Photo Barend Nagel
Nhlanhla Simelane
Nhlanhla Simelane is a second-year Language Practice student, majoring in South African Sign Language. He is also a former Chairperson of Signals – a student association that is aimed at promoting SASL and Deaf awareness.

Opinion article by Nhlanhla Simelane, Student Assistant: South African Sign Language and Deaf Studies, Faculty: The Humanities, University of the Free State.

It has been a year since the president signed off on the amendment bill to include South African Sign Language (SASL) as one of the country’s official languages. And one may wonder, what has changed since then? After all, many individuals and organisations, including the Deaf Federation of South Africa (DeafSA), the National Institute for the Deaf (NID), and Deaf rights activists from the Deaf community, believed that official recognition of sign language would lead to significant developments for SASL and the Deaf community.

Since then, SASL has mostly benefited from exposure from the SASL Indabas that PanSALB held on 9-10 March 2023 and another one on the 1-2 February this year. These Indabas were aimed at “discussing the standardisation of SASL and mapping a way forward”. They included several stakeholders, including our very own institution. They also had an impact on the development of SASL in various institutions, including UNISA and University of Cape Town (UCT), and it is hoped that this influence will extend to other institutions.

However, one must not overlook the fact that despite being a minority language, SASL already enjoyed significant language rights. For example, the South African Schools Act recognised it as an official language in 1996. The Use of Official Languages Act of 2012 provided another benefit that was not even enjoyed by the other 11 official languages; with this act, state entities had to establish a language policy outlining the use of official languages for public communication, specifically if a member of the public chose SASL as their preferred language. It also benefited from protection under the South African Sign Language Charter, launched by the SASL NLB (National Language Board) in 2020, roughly three years before it became official. Even Prof Theodorus du Plessis, Professor Emeritus in the Department of South African Sign Language and Deaf Studies, University of the Free State (UFS), in a previous opinion article, mentioned that there would be little to gain from officially recognising SASL, aside from the added symbolism associated with such a move. As a matter of fact, SASL had more to lose than gain due to its official recognition, as you will learn later in the article.

A human rights level

On a human rights level, which is more relevant to those living with hearing impairments in the country, the officialisation of SASL still had no significant effect on any of their human rights. This is simply because these persons already enjoyed their rights. However, what the officialisation cost the Deaf community* is the privilege as mentioned earlier that the Use of Official Languages Act of 2012 provided – users of SASL having the right to choose SASL as their language of interaction with the state – the very one that official languages do not enjoy. This is thus a disadvantage to the Deaf community, considering that they already suffer from a lack of interpreters in the county. An article by Nicky Bezuidenhout early this year highlighted that there is a “lack of access to crucial services like healthcare and justice due to a shortage of qualified South African Sign Language (SASL) interpreters”. Therefore, many Deaf people rely on untrained or unqualified individuals and mostly even family members to act as interpreters. This was mostly the case in my life, being a CODA (Child of a Deaf Adult) and having to interpret for my parents. And besides my proficiency in SASL, there was still the matter of a breach of confidentiality. This is a common problem for many people. Therefore, more SASL interpreters (SASLi) are needed. Additionally, it is up to everyone to take it upon themselves to learn SASL through the various provisions that are available today.

More development for SASL as a language

Thankfully, the UFS, among a few other institutions such as the Wits University, North-West University as well as the Durban University of Technology, makes such a provision through its SASL short course. Another way to learn is through mobile applications such as DEAFinition and the NID SASL Dictionary. The previous platforms also offer inexpensive online courses. This way, one can be equipped with SASL fundamentals to at least be able to hold a conversation without the need for an interpreter. Furthermore, we can only anticipate that since SASL is officially recognised, it will become more accessible in higher education institutions, as mentioned earlier, and will be included in the South African school curriculum, particularly for mainstream schools. As a result, more people will have the opportunity to learn SASL. Moreover, we can expect to see an increase in the number of qualified teachers with not only teaching skills but also proficiency in SASL.

Nonetheless, it has only been a year and matters regarding language plans and policies often require a great amount of resources, with time being the greatest of all. We can only hope that its officialisation has indeed led to the cultural acceptance of SASL and the relevant community, promoting substantive equality, and preventing unfair discrimination based on disability. But more importantly, we hope that this is not the end of the road for SASL in terms of its development as a language.

*Footnote: It is important to make a distinction between deaf people who are deaf but do not identify as part of the Deaf community and do not use SASL (who are referred to with a lowercase “d’’), and those who are deaf and are part of the Deaf community, making use of SASL as their first language (who are referred to using a capitalised ‘D’).

• Nhlanhla Simelane is a second-year Language Practice student, majoring in South African Sign Language. He is also a former Chairperson of Signals – a student association that is aimed at promoting SASL and Deaf awareness.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept